Results 1 - 10 of 19 : 1 2 Next
Good data, but will the FDA agree?
See what the best CAPS players recommend now.
Drugmaker Isis must complete cancer tests before submitting its marketing application.
Headache Over for Pozen and Glaxo?
The duo's FDA headache is over, but a new one is about to begin.
Upsetting the agency that approves drugs is never a good move.
FDA approval of a combination drug doesn't leave Merck trembling.
Headache Almost Over for Pozen
The drug is safe; hopefully that's all the FDA wanted to know.
Pozen plans a just-in-case safety trial.
Wednesday's Worst Stocks in the World
It had to be some company.
Will Pozen's response to its second approvable letter be enough?
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK